Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02859259 · ClinicalTrials.gov registry record · Phase 1
A Study of the Relative Bioavailability of BMS-626529 Administered as BMS-663068 From 150mg Low-dose Extended-release Tablets Compared to 600mg Reference Extended-release Tablets in Healthy Subjects
A Phase 1 study, sponsored by ViiV Healthcare.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT02859259 is a Phase 1 study that has completed, run by ViiV Healthcare. The registered enrollment target is 14 participants.
The verdict
NCT02859259, a Phase 1 study, has completed, sponsored by ViiV Healthcare.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
An oral dose in healthy subjects to determine the relative bioavailabilty of BMS-626529 administered as BMS-663068
Interventions
- DRUG BMS-663068 (1 tablet at 600 mg)
- DRUG BMS-663068 (4 tablets at 150 mg each tablet)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2016-08-12 |
| Est. Completion | 2016-08-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02859259
The ClinicalTrials.gov registry entry for NCT02859259 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ViiV Healthcare, which has 182 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BMS-663068 (1 tablet at 600 mg) is the first listed.
NCT02859259 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02859259 about?
NCT02859259 is a clinical study titled "A Study of the Relative Bioavailability of BMS-626529 Administered as BMS-663068 From 150mg Low-dose Extended-release Tablets Compared to 600mg Reference Extended-release Tablets in Healthy Subjects". An oral dose in healthy subjects to determine the relative bioavailabilty of BMS-626529 administered as BMS-663068
What is the current status of trial NCT02859259?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2016-08-12. Estimated completion is 2016-08-12.
What interventions are being tested in trial NCT02859259?
The interventions under investigation include: BMS-663068 (1 tablet at 600 mg) (DRUG), BMS-663068 (4 tablets at 150 mg each tablet) (DRUG).
Who is sponsoring clinical trial NCT02859259?
This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.